2 More Potential Biotech Buyout Targets [Seeking Alpha]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Seeking Alpha
The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints. Looking for a helping hand in the market? Members of The Biotech Forum get exclusive ideas and guidance to navigate any climate. Learn More » On Tuesday, I posted an article around three biotech/biopharma mid-cap concerns that make logical buyout targets for larger players in the pharma space. As noted in the previous article, there are many reasons to believe the M&A will remain active in this sector. Among these are the huge amounts of cash on the balance sheets of major drug firms, some key patent expirations over the next few years, and dramatically dropping revenue from Covid-related products like vaccines and therapeutics. That article focused on companies targeting areas outside of oncology
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- EXEL vs. REGN: Which Stock Is the Better Value Option? [Yahoo! Finance]Yahoo! Finance
- Global Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical Developments [Yahoo! Finance]Yahoo! Finance
- Pheochromocytoma Pipeline Insight Report 2024, Featuring Genentech, Exelixis, Advanced Accelerator Applications, Enterome, FUJIFILM Toyama Chemical, Ipsen, Pfizer and Astex Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Institutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growth [Yahoo! Finance]Yahoo! Finance
- Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024Business Wire
EXEL
Earnings
- 2/6/24 - Beat
EXEL
Sec Filings
- 4/18/24 - Form ARS
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form DEF
- EXEL's page on the SEC website